Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.56 |
| ▸ | FABP1 | P07148 | 3/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1096131 | 0.99 | NR1H4 (0.55) | NR1H4FABP1GPBAR1FABP4HSD17B13 | |
| SCHEMBL1095590 | 0.96 | NR1H4 (0.59) | NR1H4FABP1GPBAR1FABP4HSD17B13 | |
| Hydrochloric Acid SCHEMBL1096206 | 0.95 | NR1H4 (0.58) | NR1H4FABP1GPBAR1FABP4HSD17B13 | |
| SCHEMBL21264346 | 0.90 | NR1H4 (0.62) | NR1H4FABP1GPBAR1FABP4HSD17B13 | |
| SCHEMBL21703707 | 0.90 | NR1H4 (0.62) | NR1H4FABP1GPBAR1FABP4HSD17B13 | |
| SCHEMBL22570854 | 0.89 | NR1H4 (0.55) | NR1H4FABP1GPBAR1FABP4HSD17B13 | |
| SCHEMBL25515551 | 0.89 | NR1H4 (0.61) | NR1H4FABP1GPBAR1FABP4HSD17B13 | |
| SCHEMBL24599092 | 0.88 | NR1H4 (0.51) | NR1H4 | |
| Hydrochloric Acid SCHEMBL29089586 | 0.87 | NR1H4 (0.50) | NR1H4 | |
| SCHEMBL24599036 | 0.86 | NR1H4 (0.58) | NR1H4FABP1FABP4HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271377-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | Terns Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116887827-A | Compounds and methods for modulating FXR | 拓臻制药公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022147448-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | TERNS PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022147448-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | TERNS PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20220213083-A1 | FXR SMALL MOLECULE AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF | VAN ANDEL RESEARCH INSTITUTE | 2022-07-07 | — | — | US | disclosed |
| WO-2020211872-A1 | FXR SMALL MOLECULE AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2020-10-22 | — | — | WO | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2178851-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | Eli Lilly & Company (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213083-A1 | FXR SMALL MOLECULE AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF | FXR1, NR1H4, FXR2 | NR1H4 2/4885FABP1 40/4885GPBAR1 4/4885 |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | NR1H4 1/4885FABP1 10/4885GPBAR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.